Advancing Standards in Regenerative Medicine Act

Bill: 114-hr-4669
Sponsor: full_name: Rep. Foster, Bill [D-IL-11]
Introduced: 2016-03-02
Policy area: Health
Subjects: Cell biology and embryology

Drug safety, medical device, and laboratory regulation

Genetics

Medical research

Organ and tissue donation and transplantation

Public-private cooperation
Latest action: action_date: 2016-03-04
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2016-03-02
action_desc: Introduced in House
text: <p><b>Advancing Standards in Regenerative Medicine Act</b></p> This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to facilitate the establishment of a public-private Standards Coordinating Body in Regenerative Medicine and Advanced Therapies. The FDA must work with this body to develop standards to support the development and review of regenerative medicine products.

tv_txt: I 114th CONGRESS 2d Session H. R. 4669 IN THE HOUSE OF REPRESENTATIVES March 2, 2016 Mr. Foster introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To support the establishment of a Standards Coordinating Body in Regenerative Medicine and Advanced Therapies.

1. Short title This Act may be cited as the Advancing Standards in Regenerative Medicine Act . 2. Support for the establishment of a standards coordinating body in regenerative medicine and advanced therapies Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq. ) is amended by inserting after section 506F the following: 506G. Coordinating body in regenerative medicine and advanced therapies (a) In general The Secretary, in consultation with stakeholders, including regenerative medicine product manufacturers and clinical trial sponsors, contract manufacturers, academic institutions, standard setting organizations, the National Institute of Standards and Technology, and other relevant Federal agencies, as appropriate, shall facilitate establishment of a public-private Standards Coordinating Body in Regenerative Medicine and Advanced Therapies. (b) Function of standards coordinating body Upon establishment of the Standards Coordinating Body in Regenerative Medicine and Advanced Therapies under subsection (a), the Secretary shall— (1) identify opportunities for the development of laboratory regulatory science research and documentary standards that the Secretary determines would support the development, evaluation, and review of regenerative medicine products; and (2) work with such Standards Coordinating Body, as appropriate, in the development of standards described in paragraph (1). (c) Guidance The Secretary shall issue guidance, as appropriate, on how standards may be used in regulatory review for regenerative medicine and advanced therapies. (d) Definition For purposes of this section, the term regenerative medicine and advanced therapies includes cell therapy, gene therapy, gene-modified cell therapy, therapeutic tissue engineering products, and human cell and tissue products, and combination products using any such therapies or products. (e) No additional funds The Secretary shall carry out this section using funds otherwise made available to the Food and Drug Administration. No additional funds are authorized to be appropriated to carry out this section. .